MOT™ Platform
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Multiple Sclerosis
Research/DiscoveryActive
Key Facts
Indication
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, Multiple Sclerosis
Phase
Research/Discovery
Status
Active
Company
About MitoSense
MitoSense is a private, preclinical-stage biotech founded in 2017, pioneering a first-in-class cellular biotherapy based on transplanting functional mitochondria. Its lead focus is on Amyotrophic Lateral Sclerosis (ALS), with potential applications across a broad spectrum of neurodegenerative disorders. The company leverages an experienced leadership team and is built upon foundational research by Dr. Robert Elliott, positioning it to address major unmet medical needs in a large and growing market.
View full company profile